Informations générales (source: ClinicalTrials.gov)
Characterisation of the Immune Infiltrate and Molecular Features of Thymic Epithelial Tumors Tumors (TETs) (IMMUNO-TET)
Interventional
N/A
Institut Curie (Voir sur ClinicalTrials)
août 2023
octobre 2026
05 avril 2025
The IMMUNO-TET trial aims to assess the feasibility of characterising the immune
environment of TETs and the constitutional and somatic molecular profiles of patients
with localised thymic epithelial tumour (TET).
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| HOPITAL FOCH | EDOUARD SAGE | 07/04/2025 07:02:29 | Contacter | ||
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| CLCC INSTITUT CURIE | Nicolas Girard, MD | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Hôpital FOCH - Suresnes - France | Edouard SAGE, MD | Contact (sur clinicalTrials) | |||
| Institut Mutualiste Montsouris - Paris - France | Alessio MARIOLO, MD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
1. Patient with suspicion of localised thymic epithelial tumour.
2. Age ≥ 18 years.
3. Treatment-naïve patient for this disease.
4. Patient with an indication for thymectomy and thymomectomy in one of the partner
centers.
5. Signed informed consent form of the patient.
1. Patient with suspicion of localised thymic epithelial tumour.
2. Age ≥ 18 years.
3. Treatment-naïve patient for this disease.
4. Patient with an indication for thymectomy and thymomectomy in one of the partner
centers.
5. Signed informed consent form of the patient.
1. Neoadjuvant chemotherapy.
2. No social security affiliation.
3. Person under legal protection.
4. Other neoplasia in progress or cured within the last 3 years (except for operated
carcinoma in situ).